Results 171 to 180 of about 29,631 (205)

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial. [PDF]

Front Immunol
Batmunkh T, Neal EF, Amraa O, Mazarakis N, Altangerel B, Avaa N, Batbayar L, Batsukh K, Bright K, Burentogtokh T, Do LAH, Dorj G, Hart JD, Jamiyandorj O, Javkhlantugs K, Jigjidsuren S, Justice F, Li S, Mashbaatar K, Moore KA, Namjil N, Nguyen CD, Ochirbat B, Surenjav U, Thomson H, Tsolmon B, Licciardi PV, von Mollendorf C, Mulholland K.   +28 more
europepmc   +1 more source

Giant Cell Arteritis Following COVID-19 Vaccination: A Consumer-Stimulated Analysis. [PDF]

Drug Saf
Shetty AN, Mallard JH, Hennessy D, Wood N, Clothier HJ, Buttery JP, SAFESIG–GP Primary Health Network (PHN) Collaboration Group.   +6 more
europepmc   +1 more source

Acute tubulointerstitial nephritis following a coronavirus disease 2019 vaccine booster dose: a pediatric case report. [PDF]

CEN Case Rep
Sakaguchi H, Hirano D, Takemasa Y, Hiwatari Y, Yoshizawa S, Shoji Y, Saito A, Umeda C, Miwa S, Ito A, Oishi K.   +10 more
europepmc   +1 more source

Acquired Pure Red Cell Aplasia Following BNT162b2 mRNA COVID-19 Vaccination. [PDF]

Intern Med
Hayase N, Kaneda Y, Fukuno K, Kanemura N.   +3 more
europepmc   +1 more source

Progressive Dissociation Between Reactogenicity and Immunogenicity After Four-Dose BNT162b2 Vaccination: A 36-Month Longitudinal Study. [PDF]

Vaccines (Basel)
Zember S, Bodulić K, Balent NC, Markotić A, Đaković Rode O.   +4 more
europepmc   +1 more source

Factors influencing Anti-SARS-CoV-2 IgG levels after vaccination in breast cancer patients. [PDF]

Discov Oncol
Shueng PW, Ting WC, Chang CC, Chang WW, Tseng YJ, Chang CF, Chen GD.   +6 more
europepmc   +1 more source

Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform. [PDF]

PLoS One
Volkman HR, de Munter L, Nguyen JL, Tran TMP, Mitratza M, Marques C, Choi L, Valluri S, Yang J, Antón A, Casas I, Conde-Sousa E, Drikite L, Grüner B, Icardi G, Ten Kate GL, Martin C, Mira-Iglesias A, Orrico-Sánchez A, Otero-Romero S, Rohde G, Jodar L, McLaughlin JM, Bollaerts K.   +23 more
europepmc   +1 more source

BNT162b2 vaccine for prevention of COVID-19

, 2021
openaire   +1 more source

N-terminal pyroglutamylation of an HLA-A24-restricted immunodominant epitope enhances SARS-CoV-2-specific T-cell responses. [PDF]

Front Immunol
Aritsu Y, Kitabatake M, Kurose A, Hamana H, Nakama T, Yamada K, Furukawa R, Ouji-Sageshima N, Hara A, Yasuike K, Itami S, Li H, Udaka K, Kishi H, Ueno T, Nakagawa S, Ito T, Kawashita N, Kitamatsu M, Motozono C.   +19 more
europepmc   +1 more source

Correction: Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. [PDF]

PLoS Pathog
PLOS Pathogens Editors.
europepmc   +1 more source